Plasmalogens are usually discussed as a slow story: levels that drift down across decades and track with brain aging. Sepsis is the opposite case. It is an acute collapse, measured in hours, and it is one of the few settings where researchers have watched plasmalogen levels fall fast in real patients. That makes the literature genuinely informative about what these lipids do under oxidative attack. It also makes it very easy to misread as a supplement argument, which it is not. Nothing on this page is medical advice, and nobody who is acutely ill should be taking supplement decisions from a research summary.
Key Takeaways
- In 20 elderly patients sampled within 24 hours of severe sepsis onset, the plasmalogen marker 16:0 DMA was 55% lower than in 20 sex- and age-matched healthy controls, 0.26 plus or minus 0.15 against 0.58 plus or minus 0.13 g/100g, p below 0.001[1].
- That same study found the marker did not correlate with APACHE II score, with severity of illness, or with survival. It tracked inversely with C-reactive protein and with nothing else, and its authors called for serial measurements before it is treated as a sepsis marker at all.
- The fall is selective, not a general lipid crash. A 2022 study found plasmenylethanolamine species dropped while ordinary diacyl phosphatidylethanolamine and phosphatidylcholine actually rose[2].
- Human neutrophils carry very-long-chain plasmalogens found in no other pool, and on activation myeloperoxidase converts them into chlorinated fatty aldehydes and acids that are measurably elevated in sepsis plasma[3]. That is a route by which the lipid is consumed rather than simply under-produced.
- No trial has given a plasmalogen supplement to a septic or critically ill patient. Every study here measured a marker in people who were already severely ill.
What Was Actually Measured, and In Whom
The cleanest human number comes from a 2013 study of 20 elderly patients with initial severe sepsis, sampled within 24 hours of symptom onset and compared against 20 sex- and age-matched healthy individuals. The researchers measured plasmalogen-derived hexadecanal dimethyl acetal, written 16:0 DMA, by gas chromatography, as a proxy for the plasmalogen vinyl ether bond. Patients came in 55% lower than controls, and the gap was highly significant[1]. The chemistry behind using that bond as an oxidative-stress readout is the same chemistry described in our article on the plasmalogen antioxidant mechanism.
A 2022 study went further and asked which plasmalogen species move. In septic patient plasma, multiple plasmenylethanolamine species were reduced against both an ordinary control group and an age-aligned one, and lysoplasmenylcholine was reduced as well. Meanwhile diacyl phosphatidylethanolamine and phosphatidylcholine, the non-ether equivalents, were elevated. The same pattern reproduced in rats given cecal slurry sepsis, where kidney plasmenylethanolamine and lysoplasmenylcholine also fell[2]. The selectivity is the informative part. Whatever is happening is specific to the ether-linked pool rather than a bulk loss of membrane phospholipid, which is what you would expect from simple dilution or malnutrition.
A Mechanism For Where The Lipid Goes
A 2021 paper reported something that had not been described before: the human neutrophil plasmenylethanolamine pool contains very-long-chain species carrying 20, 22 and 24 carbon vinyl-ether groups at the sn-1 position, and these were found only in the neutrophil pool. When neutrophils are activated, myeloperoxidase oxidises those species into very-long-chain 2-chlorofatty aldehyde and then 2-chlorofatty acid, and plasma concentrations of that chlorinated product are elevated in human sepsis[3].
Read plainly, that is a consumption mechanism. The immune response itself burns through a specific lipid pool and leaves an identifiable chemical residue behind. It reframes what a low reading means: not necessarily a nutritional shortfall, but the footprint of an activated immune system. Our page on plasmalogens in immune function covers the broader immune role, and the peroxisomal synthesis pathway explains why the supply side cannot simply be turned up on demand.
Sepsis-Induced Lung Injury and COVID-19
A 2023 targeted metabolomics study analysed 54 patients with sepsis-induced acute respiratory distress syndrome against 30 non-ARDS controls, drawn from a sepsis registry collected prospectively between 2011 and 2018. Of 186 metabolites detected, 102 distinguished the ARDS patients from controls, and the main discriminating metabolites were lysophosphatidylethanolamine plasmalogen, phosphatidylethanolamine plasmalogens and phosphatidylcholines. Direct and indirect sepsis-induced ARDS separated from each other as well, there on lysophosphatidylcholines[4].
A large 2021 multi-omic study of 128 blood samples from COVID-positive and COVID-negative patients across a range of severities mapped 219 molecular features to disease status and severity, and reported plasmalogens covarying with apolipoproteins among the sets of molecules that moved together[5]. That is a correlation identified inside a screen of thousands of measurements rather than a plasmalogen result as such, and it deserves to be read at exactly that weight.
The Limit The Original Authors Set Themselves
The 2013 paper is unusually candid and worth restating in substance. The 16:0 DMA level correlated negatively with C-reactive protein, in all patients and more strongly in the subgroup who did not survive. It did not correlate with APACHE II score, creatinine, white blood cell count or platelet count, and it did not correlate with outcome or with severity of illness. The authors concluded that serial measurements would be needed before the marker could be validated in sepsis at all[1].
So the honest summary is narrow. Plasmalogens fall sharply and selectively in acute severe infection, there is a credible mechanism for why, and the size of the fall does not currently tell anyone who will do badly. A low level in an acutely infected patient and a low level in a healthy older adult are not the same finding, and the available testing options are described separately for the second case.
What This Does Not Support
It does not support taking a plasmalogen supplement to prevent or treat sepsis. No such trial exists. It does not establish that the low level causes harm rather than recording it, and a marker that reflects how hard the immune system is working will not necessarily improve anything when raised directly. It also says nothing about dosing, because no dose was ever given. Our evidence-tier summary sets out which plasmalogen claims have human trial support and which do not, and for readers who have decided separately to try a supplement for age-related reasons, the buyer guide covers what to look for. Acute illness is a hospital matter, not a supplement one.
Frequently Asked Questions
Do plasmalogen levels drop in sepsis?
Yes. In 20 elderly patients sampled within 24 hours of severe sepsis onset, the plasmalogen marker 16:0 DMA was 55% lower than in 20 sex- and age-matched healthy controls, 0.26 against 0.58 g/100g. A separate 2022 study found the drop is selective to ether-linked species, while ordinary diacyl phosphatidylethanolamine and phosphatidylcholine rose.
Does a low plasmalogen level predict who survives sepsis?
No. The 2013 study that measured the 55% drop reported the marker did not correlate with APACHE II score, with severity of illness, or with outcome. It correlated inversely with C-reactive protein and with nothing else. Its authors called for serial measurements before the marker is used in sepsis at all.
Why would plasmalogens fall during infection?
One documented route is consumption by the immune response itself. Human neutrophils carry very-long-chain plasmalogen species found in no other pool, and on activation myeloperoxidase oxidises them into chlorinated fatty aldehydes and acids. Those chlorinated products are measurably elevated in the plasma of septic patients.
Should anyone take a plasmalogen supplement for sepsis?
No. No trial has given a plasmalogen supplement to a septic or critically ill patient. Every study in this area measured a marker in people who were already acutely ill. Acute infection is managed in hospital and is not a setting for self-directed supplement decisions.
References
- Brosche T, Bauer M, Platt D, et al. Reduced plasmalogen concentration as a surrogate marker of oxidative stress in elderly septic patients. Archives of gerontology and geriatrics (2013). PMID 23522521
- Pike DP, McGuffee RM, Geerling E, et al. Plasmalogen Loss in Sepsis and SARS-CoV-2 Infection. Frontiers in cell and developmental biology (2022). PMID 35784479
- Hartman CL, Duerr MA, Albert CJ, et al. Identification of novel neutrophil very long chain plasmalogen molecular species and their myeloperoxidase mediated oxidation products in human sepsis. Redox biology (2021). PMID 34902676
- Kim S, Jeon K, Kim HJ, et al. A targeted metabolomics approach for sepsis-induced ARDS and its subphenotypes. Critical care (London, England) (2023). PMID 37408042
- Overmyer KA, Shishkova E, Miller IJ, et al. Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell systems (2021). PMID 33096026
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
